The kit was created during their time as undergraduates under the mentorship of Qi, a CRISPR/Cas9 researcher. Qi believes that college students are critical in making biotechnologies within the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

CRISPR Therapeutics (NASDAQ: CRSP) stock climbed 7% after receiving an upgrade from Evercore ISI, shifting from an In Line rating to Outperform. The biotechnology company, known for its CRISPR/Cas9 ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...